Laura L Reimers1, Katherine D Crew2,3,4, Patrick T Bradshaw5, Regina M Santella6,4, Susan E Steck7, Iryna Sirosh6, Mary Beth Terry2,4, Dawn L Hershman2,3,4, Elizabeth Shane3, Serge Cremers3, Elzbieta Dworakowski3, Susan L Teitelbaum8, Alfred I Neugut2,3,4, Marilie D Gammon9. 1. Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 W 168th St, 7th Floor, New York, NY, 10032, USA. llr2124@columbia.edu. 2. Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 W 168th St, 7th Floor, New York, NY, 10032, USA. 3. Department of Medicine, Columbia University, New York, NY, USA. 4. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. 5. Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA. 6. Department of Environmental Health, Columbia University, New York, NY, USA. 7. Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA. 8. Department of Preventive Medicine, Mt. Sinai School of Medicine, New York, NY, USA. 9. Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Abstract
PURPOSE: Studies of vitamin D-pathway genetic variants in relation to cancer risk have been inconsistent. We examined the associations between vitamin D-related genetic polymorphisms, plasma 25-hydroxyvitamin D [25(OH)D], and breast cancer risk. METHODS: In a population-based case-control study of 967 incident breast cancer cases and 993 controls, we genotyped 25 polymorphisms encoding the vitamin D receptor (VDR) gene, 1α-hydroxylase (CYP27B1), 24-hydroxylase (CYP24A1), and vitamin D-binding protein (GC) and measured plasma 25(OH)D. We used multivariable logistic regression to estimate adjusted odds ratios (ORs) and 95 % confidence intervals (CIs). RESULTS: Among CYP24A1 polymorphisms, rs6068816 was associated with a 72 % reduction in breast cancer risk (TT vs. CC, OR 0.28, 95 % CI 0.10-0.76; p trend = 0.01), but for rs13038432, the 46 % decrease included the null value (GG vs. AA, OR 0.54, 95 % CI 0.17-1.67; p trend = 0.03). Increased risk that included the null value was noted for CYP24A1 rs3787557 (CC vs. TT, OR 1.34, 95 % CI 0.92-1.89). The VDR polymorphism, TaqI (rs731236), was associated with a 26 % risk reduction (TT vs. CC, OR 0.74, 95 % CI 0.56-0.98; p trend = 0.01). For other polymorphisms, ORs were weak and included the null value. The inverse association for plasma 25(OH)D with breast cancer was more pronounced (OR 0.43, 95 % CI 0.27-0.68) among women with the common allele for CYP24A1, rs927650 (p for interaction on a multiplicative scale = 0.01). CONCLUSION: Breast cancer risk may be associated with specific vitamin D-related polymorphisms, particularly CYP24A1. Genetic variation in the vitamin D pathway should be considered when designing potential intervention strategies with vitamin D supplementation.
PURPOSE: Studies of vitamin D-pathway genetic variants in relation to cancer risk have been inconsistent. We examined the associations between vitamin D-related genetic polymorphisms, plasma 25-hydroxyvitamin D [25(OH)D], and breast cancer risk. METHODS: In a population-based case-control study of 967 incident breast cancer cases and 993 controls, we genotyped 25 polymorphisms encoding the vitamin D receptor (VDR) gene, 1α-hydroxylase (CYP27B1), 24-hydroxylase (CYP24A1), and vitamin D-binding protein (GC) and measured plasma 25(OH)D. We used multivariable logistic regression to estimate adjusted odds ratios (ORs) and 95 % confidence intervals (CIs). RESULTS: Among CYP24A1 polymorphisms, rs6068816 was associated with a 72 % reduction in breast cancer risk (TT vs. CC, OR 0.28, 95 % CI 0.10-0.76; p trend = 0.01), but for rs13038432, the 46 % decrease included the null value (GG vs. AA, OR 0.54, 95 % CI 0.17-1.67; p trend = 0.03). Increased risk that included the null value was noted for CYP24A1rs3787557 (CC vs. TT, OR 1.34, 95 % CI 0.92-1.89). The VDR polymorphism, TaqI (rs731236), was associated with a 26 % risk reduction (TT vs. CC, OR 0.74, 95 % CI 0.56-0.98; p trend = 0.01). For other polymorphisms, ORs were weak and included the null value. The inverse association for plasma 25(OH)D with breast cancer was more pronounced (OR 0.43, 95 % CI 0.27-0.68) among women with the common allele for CYP24A1, rs927650 (p for interaction on a multiplicative scale = 0.01). CONCLUSION:Breast cancer risk may be associated with specific vitamin D-related polymorphisms, particularly CYP24A1. Genetic variation in the vitamin D pathway should be considered when designing potential intervention strategies with vitamin D supplementation.
Authors: A L Lauridsen; P Vestergaard; A P Hermann; C Brot; L Heickendorff; L Mosekilde; E Nexo Journal: Calcif Tissue Int Date: 2005-05-05 Impact factor: 4.333
Authors: Pia Sillanpää; Ari Hirvonen; Vesa Kataja; Matti Eskelinen; Veli-Matti Kosma; Matti Uusitupa; Harri Vainio; Katja Mitrunen Journal: Pharmacogenetics Date: 2004-04
Authors: Barbara J Fuhrman; D Michal Freedman; Parveen Bhatti; Michele M Doody; Yi-Ping Fu; Shih-Chen Chang; Martha S Linet; Alice J Sigurdson Journal: Anticancer Res Date: 2013-02 Impact factor: 2.480
Authors: Anurupa Chakraborty; Ashwani K Mishra; Abha Soni; Thodum Regina; R Mohil; D Bhatnagar; A Bhatnagar; Chintamani Chintamani; P C Sharma; Sunita Saxena Journal: Cancer Detect Prev Date: 2009
Authors: Katie M O'Brien; Dale P Sandler; H Karimi Kinyamu; Jack A Taylor; Clarice R Weinberg Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-10-25 Impact factor: 4.254
Authors: Joy Shi; Anne Grundy; Harriet Richardson; Igor Burstyn; Johanna M Schuetz; Caroline A Lohrisch; Sandip K SenGupta; Agnes S Lai; Angela Brooks-Wilson; John J Spinelli; Kristan J Aronson Journal: Tumour Biol Date: 2015-12-02
Authors: Tess V Clendenen; Wenzhen Ge; Karen L Koenig; Tomas Axelsson; Mengling Liu; Yelena Afanasyeva; Anne Andersson; Alan A Arslan; Yu Chen; Göran Hallmans; Per Lenner; Tomas Kirchhoff; Eva Lundin; Roy E Shore; Malin Sund; Anne Zeleniuch-Jacquotte Journal: PLoS One Date: 2015-10-21 Impact factor: 3.240